Zoetis appoints Iris Knobloch to board as Zoetis stock holds value
Published on 10/15/2026 at 12:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBoard appointment and earnings pressure
- Zoetis appointed Iris Knobloch to its board on October 13, 2026, expanding it to 13 members.
- Second-quarter 2026 revenue reached USD 2.47 billion, while full-year revenue guidance fell to USD 9.12 billion to USD 9.32 billion.
- Zoetis stock trades at EUR 67.41 at 12:39 p.m. CEST at Lang & Schwarz on October 15, 2026, 0.10 percent below the Xetra close of October 14, 2026.
Zoetis (ISIN US98978V1035) appointed Iris Knobloch to its board on October 13, 2026, with the board expanding from 12 to 13 members on December 1. According to Yahoo Finance, the appointment adds experience in consumer strategy and digital transformation as Zoetis manages weaker companion-animal demand.
Guidance reflects a difficult quarter
Zoetis reported USD 2.47 billion in second-quarter 2026 revenue, while adjusted net income declined 2 percent to USD 781 million. The company cut full-year organic operational revenue guidance to a decline of 3 percent to 1 percent, equal to USD 9.12 billion to USD 9.32 billion, according to Benzinga on October 6, 2026.
The pressure was concentrated in the United States, where revenue fell 7 percent in the second quarter of 2026. International revenue rose 6 percent, and the livestock segment grew 11 percent, giving investors a measurable split between the challenged pet business and stronger livestock demand.
Three events reset the investment case
On October 6, 2026, Zoetis reported USD 2.47 billion in second-quarter revenue and reduced its full-year outlook, as Benzinga reported. On October 8, 2026, the board declared a fourth-quarter dividend of USD 0.53 per share, according to Financial Times. On October 13, 2026, Zoetis announced Knobloch's board appointment and the move to 13 directors, according to Yahoo Finance.
What does the next report test?
The next test is whether companion-animal demand stabilizes before the next report. Zoetis is scheduled to review third-quarter 2026 results on November 5, 2026, at 8:30 a.m. ET, according to the company's Zoetis release. The date matters because the revised revenue range implies a 1 percent to 3 percent organic operational decline for full-year 2026.
Stock holds near its recent lows
Zoetis has a USD 31.6 billion market capitalization as of October 14, 2026. Its primary-market quote stood at USD 75.33 on the NYSE at 3:59 p.m. ET on October 14, 2026, against a 52-week range of USD 68.77 to USD 148.30. The wide range underlines how sharply expectations have changed.
Zoetis was trading at EUR 67.41 at Lang & Schwarz on October 15, 2026 at 12:39 p.m. CEST, down 0.10 percent versus the Xetra close of October 14, 2026 at EUR 67.48. The further course of trading is shown by the continuously updated real-time quote of Zoetis stock.
Zoetis stock facts
- Company: Zoetis Inc.
- ISIN: US98978V1035
- Ticker: ZTS
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 15, 2026, 12:39 p.m. CEST): EUR 67.41
- Change versus Xetra close: minus 0.10 percent
- Xetra close (October 14, 2026): EUR 67.48
- Market capitalization: USD 31.6 billion (as of October 14, 2026)
- 52-week range: USD 68.77-148.30 (as of October 14, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
Market context: Market report S&P 500.
